NEWS & EVENTS
List
Icon
-
GENOVIOR, Key Subsidiary of the Company Expands Sterile Injection Capacity to Supply Fully Synthetic Peptides & Specialty Injectables GloballyMORE > -
GENOVIOR, Key Subsidiary of the Company and MNR Therapeutics announce an non-exclusive agreement for the commercialization of Fulvestrant in the Gulf Cooperation Council (GCC) region.MORE > -
Genovior Biotech Collaboration Expands into the US Market, Signs Product Licensing Agreement to Expand Its Portfolio of Fully Synthetic Peptide PharmaceuticalsMORE > -
Genovior Biotech Collaboration Signs Exclusive Licensing Agreement with European International Company to Expand Psychiatric Drug Portfolio in the Middle East MarketMORE > -
Genovior Biotech Corp. 2025 Global Exhibition ScheduleMORE > -
Zhunan Site Dedicated Oncology(Cytotoxic) Oteracil API Plant obtained Taiwan FDA PIC/S GMP Certification.MORE >